Judge Denies Novo Nordisk Bid to Halt Lilly's Weight-Loss Drug Ads
NVO is trading near its 52-week low of $35.12 (12% above the low).
Summary
A US judge denied Novo Nordisk's request to block Eli Lilly's Zepbound and Mounjaro advertising, which Novo claimed was false and misleading. Judge Zahid Quraishi found Novo failed to show irreparable harm, noting Lilly's ads had at most a negligible market impact between April and July and that Novo prescriptions stayed stable. The ruling is a setback for Novo in the obesity and diabetes market, where it competes directly with Lilly's products. Novo said the decision did not resolve whether Lilly's advertising is false and misleading and that the litigation continues. Lilly is the immediate beneficiary of the ruling.
At the time of this announcement, NVO was trading at $39.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $172.1B. The 52-week trading range was $35.12 to $64.16. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.